Last, our results suggest that BCC tumors may respond to inflammatory signals from the stroma by expressing HSPs and that HSP inhibitors may serve as an effective therapeutic strategy to suppress HH signaling and tumor growth. This evidence concerns the gene HSP90B2P and neoplasm.